10-Q: Fortress Biotech Reports Q2 2024 Results: Revenue Declines Amidst Strategic Shifts

Fortress Biotech's Q2 2024 results show a decrease in revenue and a net loss, alongside strategic moves including debt restructuring and a pause in preferred stock dividends.

Summary

• Fortress Biotech reported a net revenue of $14.9 million for the three months ended June 30, 2024, a decrease from $17.4 million in the same period of 2023.
• The company's net loss attributable to Fortress was $10.9 million for the quarter, compared to a loss of $24.8 million in the prior year.
• For the six months ended June 30, 2024, net revenue was $27.9 million, down from $29.8 million in 2023, and the net loss attributable to Fortress was $26.4 million, compared to $46.3 million in 2023.
• The decrease in revenue is primarily due to lower sales of Journey Medical Corporation's dermatology products, particularly Qbrexza.
• Research and development expenses decreased significantly, from $32.1 million in Q2 2023 to $12.7 million in Q2 2024, due to reduced spending at Checkpoint and Mustang.
• Selling, general, and administrative expenses also decreased, from $24.4 million in Q2 2023 to $20.8 million in Q2 2024, reflecting cost-reduction efforts.
• The company has paused monthly dividend payments on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.
• Fortress entered into a new $50 million senior secured credit agreement with Oaktree, replacing a previous agreement and reducing total debt outstanding.
• Mustang Bio repurchased assets from uBriGene for $4.7 million, recognizing a $2.2 million R&D expense and classifying $2.2 million of assets as held for sale.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive signs of cost management and progress in product development, the revenue decline, continued losses, and pause in preferred stock dividends raise concerns. The company's reliance on external funding and third parties also adds to the uncertainty.

Positives

• The net loss attributable to Fortress improved significantly year-over-year, indicating progress in cost management.
• Research and development expenses decreased substantially, reflecting a more focused approach to development programs.
• Selling, general, and administrative expenses were reduced, demonstrating cost-cutting measures.
• The new credit agreement with Oaktree provides financial flexibility and reduces total debt outstanding.
• The company is progressing with key product candidates, including cosibelimab, DFD-29, and Triplex, with upcoming milestones.

Negatives

• Net revenue decreased year-over-year, primarily due to lower sales of Journey's dermatology products.
• The company continues to incur operating losses, although at a reduced rate compared to the previous year.
• The pause in dividend payments on the Series A Preferred Stock may negatively impact investor sentiment.
• The company is still reliant on third parties for manufacturing and clinical trials, which introduces risks.
• The company has a history of operating losses and expects such losses to continue in the future.

Risks

• The company's product candidates are in early stages of development and may not be successfully developed or commercialized.
• The company relies heavily on third parties for manufacturing and clinical trials, which reduces control and may hinder development.
• The company faces competition from other pharmaceutical companies, which may limit the commercial opportunity for its products.
• The company has a history of operating losses and may not achieve or sustain profitability.
• The company may need substantial additional funding and may be unable to raise capital when needed.
• The company's debt obligations may restrict its operations and ability to finance future activities.
• The company's operating income derives primarily from the sale of Journey's dermatology products, which are subject to generic competition and reimbursement risks.
• The company may be subject to costly and time-consuming litigation for infringement of third-party intellectual property rights.
• The company may not obtain the desired product labels or intended uses for product promotion, or favorable scheduling classifications.
• The company has previously failed to satisfy certain continued listing rules of Nasdaq, and may be subject to delisting if it fails to regain compliance.

Future Outlook

The company expects to continue to incur substantial losses for the next several years as it continues to fully develop and prepare regulatory filings and obtain regulatory approvals for its existing and new product candidates. The company will need to raise additional funding through strategic relationships, public or private equity or debt financings, sale of partner companies, grants or other arrangements to develop and prepare regulatory filings and obtain regulatory approvals for the existing and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for the potential products, sales and marketing capabilities.

Management Comments

• The parent Company's current cash and cash equivalents of $38.2 million are sufficient to fund the parent entity and private subsidiary operations for at least the next 12 months.
• The Board intends to revisit its decision regarding the monthly dividend regularly and will assess the profitability and cash flow of the Company to determine whether and when the pause should be lifted.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. Fortress Biotech's results reflect these challenges, with a focus on managing expenses and advancing key product candidates. The company's strategic shifts, including debt restructuring and a pause in preferred stock dividends, are indicative of efforts to navigate the current economic environment and prioritize long-term growth.

Comparison to Industry Standards

• Fortress Biotech's revenue decline is consistent with the challenges faced by many biopharmaceutical companies in early commercialization stages, where product uptake can be slower than anticipated.
• The reduction in R&D spending is a common strategy for companies seeking to optimize resources and focus on late-stage development programs, similar to actions taken by companies like Amarin and BioMarin.
• The debt restructuring and pause in preferred stock dividends are measures often taken by companies facing financial pressures, similar to actions taken by companies like Cassava Sciences and Ocugen.
• The company's reliance on third-party manufacturers and CROs is a common practice in the industry, but it introduces risks that are also faced by companies like Catalent and Lonza.
• The company's focus on acquiring and advancing assets is a strategy employed by many biotech companies, but the success of this strategy depends on the quality of the assets and the ability to integrate them effectively, similar to companies like Royalty Pharma and Ligand Pharmaceuticals.

Legal Proceedings

• Caelum Biosciences, Inc. (Caelum), a former subsidiary of Fortress, is the defendant in a lawsuit brought by The University of Tennessee Research Foundation (UTRF).
• Fortress has indemnification obligations of Caelum under certain circumstances, including for certain of Caelums legal expenses and potential damages arising out of the UTRF Litigation.

Related Party Transactions

• The Company has entered into Founders Agreements and, in some cases, exchange agreements with certain of its subsidiaries.
• The Company has entered into Management Services Agreements (the MSAs) with certain of its partner companies/subsidiaries.
• The Company has a Shared Services Agreement with TG Therapeutics, Inc. (TGTX).
• The Company has a Shared Services Agreement with Journey.
• The Company has a Desk Share Agreement with TGTX.
• Cyprium has a 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Dividend Obligation.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the pause in preferred stock dividends.
• Employees may be affected by cost-cutting measures and workforce reductions.
• Customers of Journey Medical Corporation may be affected by changes in product availability or pricing.
• Suppliers and creditors may be impacted by the company's financial performance and debt obligations.
• Clinical trial participants may be affected by delays or changes in clinical trial programs.

Next Steps

• The company will continue to develop and prepare regulatory filings for its existing and new product candidates.
• The company will assess the profitability and cash flow to determine whether and when the pause on preferred stock dividends should be lifted.
• The company will continue to seek strategic relationships, public or private equity or debt financings, sale of partner companies, grants or other arrangements to fund its operations.
• The company will continue to monitor and manage its debt obligations.

Key Dates

Keywords

Fortress Biotech, biopharmaceutical, clinical trials, drug development, revenue, net loss, research and development, Journey Medical, dermatology, Oaktree, debt, preferred stock, dividends, cosibelimab, DFD-29, Triplex, Mustang Bio, intellectual property, regulatory approval